<![CDATA[Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL]]>

Data ReadoutpositiveTisagenlecleucelPositive

AI Analysis

Summary

Updated phase 2 ELIANA trial results demonstrate tisagenlecleucel maintains durable efficacy in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia, supporting its role as a definitive therapeutic option.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Updated phase 2 ELIANA trial results demonstrate durable efficacy

Importance:6/10

Sentiment:

0.75

CAR-TPediatric oncologyHematologic malignancyDurable responsePhase 2

Related Companies

$NVS

Read the original article

Published by Cancer Network on August 7, 2026 8:00 PM

Read Original